Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)Recruiting
NCT07162480Phase 2Updated Sep 9, 2026
Sponsor: M.D. Anderson Cancer Center
Adenoid Cystic Carcinoma
United States
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Recruiting
NCT07431281Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabActive Not Recruiting
NCT06706817Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
United States, Bulgaria, Canada, France, Germany +4 more
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseRecruiting
NCT07082738Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Australia, Bulgaria, Canada +19 more
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy SubjectsCompleted
NCT05384262Phase 1Updated Sep 9, 2026
Sponsor: AstraZeneca
Dyslipidemia
United States, United Kingdom
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomRecruiting
NCT05557695N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia, CLL
United Kingdom
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFRecruiting
NCT07761117Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Heart Failure With Preserved Ejection Fraction (HFpEF) · Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
United States, Argentina, Australia, Austria, Brazil +27 more
TROP2 NMR Concordance StudyRecruiting
NCT07624318N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
Lung Cancer
China
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.Recruiting
NCT07511205Phase 1Updated Sep 9, 2026
Sponsor: AstraZeneca
Healthy Participants · Obesity
United States, United Kingdom
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabRecruiting
NCT07520162Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
China
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREARecruiting
NCT06927648N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
Breast Cancer
South Korea
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusActive Not Recruiting
NCT06530849Phase 1, Phase 2Updated Sep 9, 2026
Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.
Refractory Systemic Lupus Erythematosus
China
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active Not Recruiting
NCT05925530Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Austria, Canada, Czechia, France +6 more
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusRecruiting
NCT07430306Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Canada, France, Germany, Italy +4 more
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruiting
NCT06564038Phase 1, Phase 2Updated Sep 8, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell Lymphoma · Large B-cell Lymphoma
United States, Australia, China, Czechia, Denmark +8 more
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBEActive Not Recruiting
NCT07245407N/AUpdated Sep 8, 2026
Sponsor: AstraZeneca
Non-cystic Fibrosis Bronchiectasis
China
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPDCompleted
NCT05607719Phase 2Updated Sep 8, 2026
Sponsor: University of Miami
Chronic Obstructive Pulmonary Disease
United States
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruiting
NCT07647328Phase 3Updated Sep 8, 2026
Sponsor: AstraZeneca
ER-Positive HER2-Negative Breast Cancer
United States, France, Germany, Italy, Poland +4 more
Observational Study Protocol: LIVER-RRecruiting
NCT06252753N/AUpdated Sep 8, 2026
Sponsor: AstraZeneca
Hepatobiliary Cancers
United States, Australia, Austria, Belgium, Brazil +17 more
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active Not Recruiting
NCT07005128Phase 3Updated Sep 8, 2026
Sponsor: Amgen
Small-cell Lung Cancer · Extensive Stage Small-cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisActive Not Recruiting
NCT05047172Phase 3Updated Sep 8, 2026
Sponsor: University of Florida
Intracranial Arteriosclerosis · Stroke
United States
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaCompleted
NCT06502366Phase 3Updated Sep 8, 2026
Sponsor: AstraZeneca
Asthma
United States, China, Malaysia, Mexico, Thailand +1 more
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruiting
NCT06890598Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, Brazil +24 more
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian FederationRecruiting
NCT07041606N/AUpdated Sep 8, 2026
Sponsor: AstraZeneca
Endometrial Cancer
Russia
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursRecruiting
NCT07446855Phase 1, Phase 2Updated Sep 8, 2026
Sponsor: AstraZeneca
Solid Tumours
United States, Australia, Japan, South Korea, Spain +1 more

Previous page Next page